Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Longevixx
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict64/ 100
Grade C · #282Longevixx
A peptide catalog priced in the open, a semaglutide headline that is a first-month price, and a same-price claim above a card that steps up.
Visit LongevixxThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 64/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Longevixx still earns its place — a tirzepatide buyer, or a peptide shopper — the semaglutide headline is not the semaglutide rate.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results66
92
Real-world results66
97Price honesty46
97
Price honesty46
96Prescriber access58
96
Prescriber access58
88Formulary choice87
88
Formulary choice87
95Cancellation fairness60
95
Cancellation fairness60
93Member support72
93
Member support72
Price, coverage & features
| Metric | CoreAge Rx | Longevixx |
|---|---|---|
| Verdict Score | 94/100 | 64/100 |
| Grade | A | C |
| Semaglutide | $99/mo | $199/mo (the advertised figure is a first-month rate, compounded) |
| Tirzepatide | $149/mo | $299/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Longevixx
What we like
- Nineteen peptide programs are priced publicly on their own page, which is far more disclosure than the GLP-1 line carries
- Tirzepatide is priced at a single standing rate with no introductory discount to step off
- An oral and a microdose program sit alongside the standard injection
- A phone number, an email address and clinical hours are all published
- Auto-refill is switched off from the patient portal, and a notification lands five to seven days before each charge
The caveats
- The semaglutide headline is a first-month price; the standing rate is higher, and the homepage prints the discounted figure as a floor
- A same-price, all-dosages, everything-included claim sits directly above a card whose price rises after month one
- Two patient counts and three different average ratings are published across the site and the funnel, none of them attributed to any review platform
- The homepage says telehealth in 50 states while the contact page says the states where it is licensed and the FAQ says the states where it is available; no list exists
- Neither the microdose nor the oral program ever names its molecule, no pharmacy is named, the compounding class appears nowhere, and no clinician, medical group or NPI is published
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
A tirzepatide buyer, or a peptide shopper — the semaglutide headline is not the semaglutide rate.
Visit Longevixx Read the full Longevixx review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Longevixx does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.